Richard Gonzalez, AbbVie CEO (AP Photo/Jacquelyn Martin)
October 28, 2022 02:11 PM EDTUpdated November 16, 02:35 PM
Pharma

Ab­b­Vie preps for an on­slaught of Hu­mi­ra biosim­i­lars in 2023, with Skyrizi and Rin­voq to fill the gap for now

Zachary Brennan

Senior Editor

Un­veiled Fri­day morn­ing, Ab­b­Vie’s Q3 re­sults and earn­ings call show a com­pa­ny brac­ing for what could be steep Hu­mi­ra loss­es with the com­ing of biosim­i­lar …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times